Celldex Therapeutics, INC Form 4 insider transactions

Director Herbert J. Conrad acquired 16,500 non-qualified stock options in Celldex Therapeutics on June 13, 2024, according to a Form 4 filing.

Karen L. Shoos, a director of Celldex Therapeutics, acquired 16,500 non-qualified stock options on June 13, 2024, according to a recent SEC filing.

Harry Penner Jr., a director of Celldex Therapeutics, acquired 16,500 non-qualified stock options on June 13, 2024, under the company's 2021 Omnibus Equity Incentive Plan.

Diane C. Young, SVP, Chief Medical Officer of Celldex Therapeutics, exercised stock options and sold the acquired shares on June 11, 2024.

Elizabeth Crowley, SR. VP & CPDO of Celldex Therapeutics, exercised stock options and sold shares on June 7, 2024.

Diane C. Young, SVP, Chief Medical Officer of Celldex Therapeutics, Inc., reported the sale of 45,000 shares of common stock on June 7, 2024.

Freddy A. Jimenez, SVP & General Counsel of Celldex Therapeutics, exercised stock options and acquired 9,540 shares of common stock on June 5, 2024.

Margo Heath-Chiozzi, SVP of Regulatory Affairs at Celldex Therapeutics, exercised stock options and sold shares on June 3, 2024.

Richard M. Wright, a Senior VP & CCO at Celldex Therapeutics, reported the exercise of stock options and the sale of common stock on June 3, 2024.

Freddy A. Jimenez, SVP & General Counsel of Celldex Therapeutics, exercised stock options and sold shares on June 3, 2024.

Margo Heath-Chiozzi, SVP of Regulatory Affairs at Celldex Therapeutics, exercised stock options and sold shares of common stock on May 30, 2024.

Martin Samuel Bates, SVP and CFO of Celldex Therapeutics, exercised stock options and sold shares on May 30, 2024.

Sarah Cavanaugh, SVP of Corporate Affairs & Administration at Celldex Therapeutics, reported the exercise of stock options and sale of common stock on May 30, 2024.

Elizabeth Crowley, SR. VP & CPDO of Celldex Therapeutics, exercised stock options and sold shares on May 30, 2024.